100s of titles, one news app for just $10 a month.
Latest Business news:
World’s top fertiliser maker sees two years of high prices
In more bad news for farmers, a fertiliser that's key for crop production across the world will remain expensive for…
Read news from The Economist, FT, Bloomberg and more, with one subscription
Learn More
What will happen to the $136 million live sheep industry now Labor has won the federal election?
Farmers are waiting nervously to hear whether Labor will follow through on an election pledge to ban live sheep exports,…
To use rather than collect, the second coming of NFTs
New York (AFP) - NFTs have been called everything from fads to outright scams, but early adopters see a future…
The only way is up for NZ cash rate
Mortgage holders in New Zealand are bracing themselves for another cash-rate hit from the Reserve Bank.
Quality assurance workers at Activision Blizzard subsidiary unionize, a first at a major US gaming company
A small group of quality assurance workers at an Activision Blizzard-owned game studio have unionized, marking the arrival of the…
From analysis to good news, read the world’s best news in one place
‘Buy now, pay later’ leader Klarna slashes staff numbers as the prospect of rate increases push up its borrowing costs
Swedish ‘buy now, pay later’ company Klarna Bank saw its borrowing costs climb to their highest level on record as…
As Melbourne's night-life recovers from COVID, a liquor licence freeze brought in 13 years ago is under the microscope
The state government says the pause on the granting of new liquor licences will remain in place until June 2023.

Expert Ratings for OncoCyte

By Benzinga Insights

Within the last quarter, OncoCyte (NASDAQ:OCX) has observed the following analyst ratings:

Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish
Total Ratings 3 1 0 0 0
Last 30D 1 0 0 0 0
1M Ago 0 0 0 0 0
2M Ago 0 1 0 0 0
3M Ago 2 0 0 0 0

According to 4 analyst offering 12-month price targets in the last 3 months, OncoCyte has an average price target of $3.51 with a high of $6.00 and a low of $1.80.

Below is a summary of how these 4 analysts rated OncoCyte over the past 3 months. The greater the number of bullish ratings, the more positive analysts are on the stock and the greater the number of bearish ratings, the more negative analysts are on the stock

This current average has decreased by 39.27% from the previous average price target of $5.78.

If you are interested in following small-cap stock news and performance you can start by tracking it here.

How Are Analyst Ratings Determined?

Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.

Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.

If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in Benzinga Pro.

This article was generated by Benzinga's automated content engine and reviewed by an editor.

What is inkl?
The world’s most important news, from 100+ trusted global sources, in one place.
Morning Edition
Your daily
news overview

Morning Edition ensures you start your day well informed.

No paywalls, no clickbait, no ads
Enjoy beautiful reading

Content is only half the story. The world's best news experience is free from distraction: ad-free, clickbait-free, and beautifully designed.

Expert Curation
The news you need to know

Stories are ranked by proprietary algorithms based on importance and curated by real news journalists to ensure that you receive the most important stories as they break.